Immunic (IMUX) Return on Equity (2014 - 2026)

Immunic has disclosed Return on Equity across 13 years of filings, most recently posting 0.01% for Q1 2026.

• Return on Equity for Q1 2026 came in at 0.01%, up 14.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (up 14.0% YoY), and the FY2025 annual result was 0.17%, down 13.0% from the prior year.
• Return on Equity came in at 0.01% for Q1 2026 at Immunic, up from 0.53% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.01% in Q1 2022 to a low of 0.53% in Q4 2025.
• The 5-year median for Return on Equity is 0.02% (2024), against an average of 0.06%.
• Across the five-year window, Return on Equity plunged 50 bps in 2025 and climbed 14 bps in 2026, its largest moves.
• Immunic's Return on Equity stood at 0.01% in 2022, then plunged by 134 bps to 0.02% in 2023, then declined by 28 bps to 0.03% in 2024, then slumped by 1583 bps to 0.53% in 2025, then surged by 97 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.53% (Q4 2025), and 0.05% (Q3 2025), per Business Quant data.